Scientists track HIV prevention drug in Mothers' milk
NCT ID NCT06580587
Summary
This study aims to understand how much of an experimental HIV prevention drug (MK-8527) passes into breast milk. Researchers will measure drug levels in the breast milk, blood, and plasma of 12 healthy, lactating women over 120 hours after they take a single dose. The goal is to learn how much medication a breastfeeding infant might be exposed to, which is a critical safety step for developing new drugs for mothers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV PRE-EXPOSURE PROPHYLAXIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0002)
Springfield, Missouri, 65802, United States
-
University of Pittsburgh Medical Center Magee-Womens Hospital ( Site 0001)
Pittsburgh, Pennsylvania, 15213, United States
Conditions
Explore the condition pages connected to this study.